The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

References

• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15761078
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer, version 1. 2016. [cited 2015 Oct ]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
   Google Scholar
• de Reijke TM, Bellmunt J, van Poppel H,et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009;45:765–773.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49–56.
   PubMed Web of Science ®Google Scholar
• Powles T, Staehler M, Ljungberg B, et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol. 2016;69:4–6.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer. 2010;46:1323–1332.
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.
   PubMed Web of Science ®Google Scholar
• Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48:333–339.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257–2267.
   PubMed Web of Science ®Google Scholar
• Brugarolas JB, Vazquez F, Reddy A, et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003;4:147–158.
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004–7014.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Puente J, Garcia de Muro J, et al. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014;16:1043–1050.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601–5608.
   PubMed Web of Science ®Google Scholar
• Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012;23(Suppl 8):viii35–40.
   PubMed Web of Science ®Google Scholar
• Brugarolas J. Renal-cell carcinoma–molecular pathways and therapies. N Engl J Med. 2007;356:185–187.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–2049.
   PubMed Web of Science ®Google Scholar
• Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther. 2013;13:847–861.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–1939.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–927.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256–4265.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Roldán-Romero J, Maroto Rey P, Anguera G et al., editors. TSC2 mutations in a chromophobe renal cell carcinoma patient with extraordinary response to temsirolimus. The European Human Genetics Conference; 2016 May 21-24; Barcelona (Spain).
   Google Scholar
• European Medicines Agency. Product information temsirolimus (Torisel®, Pfizer). [cited 2015 Oct]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000799/WC500039912.pdf
   Google Scholar
• European Medicines Agency. Product information everolimus (Afinitor®, Novartis). [cited 2015 Oct]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf
   Google Scholar
• Iacovelli R, Santoni M, Verzoni E, et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer. 2015;13:137–141.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Carteni G, Milella M, et al. Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. Can Urol Assoc J. 2014;8:E121–5.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:2765–2772.
   PubMed Web of Science ®Google Scholar
• Knox JJ, Barrios CH, Kim TM, et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). J Clin Oncol. 2015;33: Abstract 4554.
   Google Scholar
• Motzer R, Alyasova A, Ye D, et al. RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015;33:Abstract 4518.
   Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–1482.
   PubMed Web of Science ®Google Scholar
• Snegovoy A, Varlamov S, Safina S, et al. Everolimus in patients with metastatic renal cell carcinoma (RCC) previously treated with bevacizumab: final results of prospective multicenter study. J Clin Oncol. 2015;33:Abstract e15621.
   Google Scholar
• Koutsoukos K, Espinosa Montano M, Kontovinis L, et al. Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration. J Clin Oncol. 2015;33: Abstract e15601.
   Web of Science ®Google Scholar
• Vogelzang NJ, Kumar S, Signorovitch J, et al. Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review. J Clin Oncol. 2015;33: Abstract 500.
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760–767.
   PubMed Web of Science ®Google Scholar
• Wong MK, Jonasch E, Pal SK, et al. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother. 2015;16:805–819.
   PubMed Web of Science ®Google Scholar
• Grunwald V, Karakiewicz PI, Bavbek SE, et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012;48:324–332.
   PubMed Web of Science ®Google Scholar
• Heng DY, Signorovitch J, Swallow E, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies. Plos One. 2014;9:e114264.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Vogelzang NJ, Pal SK, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin. 2014;30:2343–2353.
   PubMed Web of Science ®Google Scholar
• Bergmann L, Kube U, Doehn C, et al. Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. BMC Cancer. 2015;15:303.
   PubMed Web of Science ®Google Scholar
• Albiges L, Kube U, Eymard JC, et al. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies. Eur J Cancer. 2015;51:2368–2374.
   PubMed Web of Science ®Google Scholar
• Oudard S, Joly F, Geoffrois L, et al. Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A French survey—The sector study. J Clin Oncol. 2014;32: Abstract 509.
   PubMed Web of Science ®Google Scholar
• Barthelemy P, Escudier B, Joly F, et al. Long-term responders to everolimus: A subgroup analysis of the sector study. J Clin Oncol. 2014;32: Abstract 462.
   Web of Science ®Google Scholar
• Oudard S, Ravaud A, Escudier B. Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: focus on mechanism of action. Ann Urol. 2011;1:19–27.
   Google Scholar
• Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev Anticancer Ther. 2011;11:639–649.
   PubMed Web of Science ®Google Scholar
• Eichelberg C, Vervenne WL, de Santis M, et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol. 2015;68:837–847.
   PubMed Web of Science ®Google Scholar
• Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008;6(Suppl 5):S1–S20; quiz S1-2.
   PubMedGoogle Scholar
• Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev. 2012;38:981–987.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–918.
   PubMed Web of Science ®Google Scholar
• White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182:396–403.
   PubMed Web of Science ®Google Scholar
• Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol. 2011;29:1750–1756.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008;19:1387–1392.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pascual J, Cheng E, Maroto P, et al. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs. 2010;21:478–486.
   PubMed Web of Science ®Google Scholar
• Duran I, Goebell PJ, Papazisis K, et al. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf. 2014;13:361–372.
   PubMed Web of Science ®Google Scholar
• Pilotte AP, Hohos MB, Polson KM, et al. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs. 2011;15:E83–E89.
   PubMedGoogle Scholar
• Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16(Suppl 2):32–44.
   PubMed Web of Science ®Google Scholar